Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 59, Issue 7, 2000, Pages 504-505

  Smolen, Josef S ^a   Van De Putte, Leo B A ^j   Van Riel, Piet L C M ^j   Rodriguez Valverde, Vicente ^k   Breedveld, Ferdinand C ^b   Burmester, Gerd R ^c   Combe, Bernard ^d   Emery, Paul ^e   Kalden, Joachim R ^f   Klareskog, Lars ^g   Maini, Ravinder N ^h   Numo, Raffele ⁱ  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LEIDEN UNIVERSITY   (Netherlands)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIV MONTPELLIER   (France)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g STOCKHOLM UNIVERSITY   (Sweden)

^h University of Charing Cross   (United Kingdom)

ⁱ UNIVERSITY OF BARI   (Italy)

^j RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^k UNIVERSITY OF CANTABRIA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; BLOCKING AGENT; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR;

ANTIINFLAMMATORY ACTIVITY; DISEASE ACTIVITY; DRUG RESISTANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; THORAX RADIOGRAPHY; TREATMENT INDICATION; TREATMENT PLANNING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; PAIN MEASUREMENT; PATIENT SELECTION; PHYSICAL EXAMINATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033949718     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.59.7.504     Document Type: Review

References (15)

1. 1 Furst DE, Breedveld FC, Burmester GR, Crooford L, Emery P, Feldmann M, et al. Consensus Statement: Access to disease modifying treatments for rheumatoid arthritis patients. Ann Rheum Dis 1999;58 (suppl I):129-30.
2. 2 van der Heijde DMFM, van Riel PLCM, Nuver-Zwart ICH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;i:1036-8.
3. 3 Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxiciry tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 1992;35:1117-25.
4. 4 Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344:1105-10.
5. 5 Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
6. 6 Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41: 1552-63.
7. 7 Maini RN, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
8. 8 Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
9. 9 Lipsky P, St Clair W, Furst D, Breedveld F, Smolen J, Kalden JR, et al. 54-week clinical and radiographic results from the ATTRACT trial: a phase III study of infliximab in patients with active RA despite methotrexate. Arthritis Rheum 1999;42 (suppl):401.
10. 10 Finck B, Martin R, Fleischmann R, Moreland L, Schiff M, Bathon J. A phase III trial of etanercept vs methotrexate (MTX) in early rheumatoid arthritis (ENBREL ERA trial). Arthritis Rheum 1999;42 (suppl):117.
11. 11 Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL, et al. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 1995;38:44-8.
12. 12 Weinblatt ME. The role of current strategies in the future treatment of rheumatoid arthritis. Rheumatology 1999; 38 (suppl 2):19-23.
13. 13 Van Gestel AM, Anderson JJ, van Riel PLCM, Boers M, Haagsma CJ, Rich B, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. J Rheumatol 1999;26:705-11.
14. 14 Felson DT, Anderson JJ, Boers M, Bombardier-C, Furst-D, Goldsmith-C, et al. The American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
15. 15 Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.